On Monday, Aldeyra Therapeutics Inc (NASDAQ: ALDX) opened higher 18.59% from the last session, before settling in for the closing price of $5.11. Price fluctuations for ALDX have ranged from $2.71 to $6.92 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -45.68% at the time writing. With a float of $57.82 million, this company’s outstanding shares have now reached $59.65 million.
Let’s look at the performance matrix of the company that is accounted for 9 employees. In terms of profitability, gross margin is 51.93%, operating margin of -12642.51%, and the pretax margin is -11409.41%.
Aldeyra Therapeutics Inc (ALDX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Aldeyra Therapeutics Inc is 2.90%, while institutional ownership is 62.83%. The most recent insider transaction that took place on Aug 12 ’24, was worth 75,975. In this transaction Chief Development Officer of this company sold 16,041 shares at a rate of $4.74, taking the stock ownership to the 236,771 shares. Before that another transaction happened on Aug 12 ’24, when Company’s insider sold 10,834 for $4.74, making the entire transaction worth $51,313. This insider now owns 126,382 shares in total.
Aldeyra Therapeutics Inc (ALDX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -45.68% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.10% during the next five years compared to 15.99% growth over the previous five years of trading.
Aldeyra Therapeutics Inc (NASDAQ: ALDX) Trading Performance Indicators
Check out the current performance indicators for Aldeyra Therapeutics Inc (ALDX). In the past quarter, the stock posted a quick ratio of 5.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.94, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach 0.14 in one year’s time.
Technical Analysis of Aldeyra Therapeutics Inc (ALDX)
Aldeyra Therapeutics Inc (NASDAQ: ALDX) saw its 5-day average volume 0.9 million, a positive change from its year-to-date volume of 0.42 million. As of the previous 9 days, the stock’s Stochastic %D was 34.13%. Additionally, its Average True Range was 0.48.
During the past 100 days, Aldeyra Therapeutics Inc’s (ALDX) raw stochastic average was set at 69.61%, which indicates a significant increase from 59.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 123.38% in the past 14 days, which was higher than the 72.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.48, while its 200-day Moving Average is $4.89. Nevertheless, the first resistance level for the watch stands at $6.64 in the near term. At $7.22, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.92. If the price goes on to break the first support level at $5.36, it is likely to go to the next support level at $4.66. Assuming the price breaks the second support level, the third support level stands at $4.08.
Aldeyra Therapeutics Inc (NASDAQ: ALDX) Key Stats
There are currently 59,550K shares outstanding in the company with a market cap of 360.87 million. Presently, the company’s annual sales total 0 K according to its annual income of -37,540 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -15,110 K.
